After four years of follow-up, KEYTRUDA plus LENVIMA reduced the risk of death by 21% versus sunitinib in the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581...
Positive clinical response as demonstrated in 8 out of 12 patients receiving EVX-01 in combination with a checkpoint inhibitor The study met prima...
On March 31, 2023, the government of the Hong Kong Special Administrative Region announced that, from April 20, high-risk groups will be able to receive fr...
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients...
Study results of novel drug-eluting technology highlight potential durability of TAR-200 in patient population with high unmet need T...
Corning Incorporated announced the launch of its Advanced Flow Pharmaceutical Technology (AFPT) services business to help contract development m...
The expansion project aims to (i) grow Virica’s bioprocessing capacity to keep pace with client demand for scaling up viral medicines, (ii) advance n...
Sanofi (EURONEXT: SAN and NASDAQ: SNY) has today announced the launch of AVAXIM® Junior in the UK, an inactive hepatitis A vaccine indicated for use in...
What You Need to Know: Most individuals, depending on age, previously vaccinated with a monovalent COVID-19 vaccine who have not yet received a dose of ...
"This collaboration represents an exciting opportunity for Nona Biosciences to leverage its fully human antibody H2L2 transgenic mice, together with the te...
The published data showcase how Evaxion's proprietary AI-platform, RAVEN (Rapidly Adaptive Viral Response), identifies broad and robust T-cell epitopes fro...
After helping to develop and test new mRNA technologies for COVID-19 vaccines, University of Maryland School of Medicine (UMSOM) researchers and scientists...
Lyme disease is the most common vector-borne illness in the United States.2 And yet, the actual cases are vastly underreported. The U.S. Centers for Diseas...
Preclinical data demonstrate the efficacy of TNX‐801 vaccination against mpox virus challenge in a non-human primate model Phase 1 trial with TN...
© 2025 Biopharma Boardroom. All Rights Reserved.
